Briacell Therapeutics Corp BCTX

$4.08 -0.08 (-1.81%)

Valuation

Market cap
36,148,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
181,800
Avg volume
323,008
Day's range
$3.97 – $4.20
Shares out
8,700,000
Stochastic %K
59%
Beta
1.10
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

Biotechlineup Sep 30, 12:59 AM
$BCTX The Phase 2 study patients who were DHT+ lived more than double the length of time compared to those who were DHT - , 11.3 months vs 4.7 months By saying this is happening in the majority of the current Phase 3 patients, management is heavily implying that most patients on the active drug arm are successfully generating the protective immune response required to extend their lives. Control Arm is of course DHT- . Unfortunately for the control arm is not doing well. That’s 2+2 speculation if management stated they are on track for Dec then the majority must be in the control arm and therefore high likelihood of a .6 HR? https://briacell.com/briacell-presents-outstanding-phase-2-survival-promising-phase-3-clinical-data-at-sabcs-2025/ <>Positive Delayed Type Hypersensitivity (DTH) may be key predictor of clinical benefit as median overall survival (OS) was significantly (P=0.0001) higher in patients who were DTH+ (11.3 months) vs those who were DTH- (4.7 months).>>
0 replies
JediGreen Sep 29, 8:40 PM
$BCTX wasn’t able to attend today. Looking forward to watching it. Probably be posted sometime this week or next week. How did it go?
2 replies
AliceFireSteam Sep 29, 8:37 PM
$BCTX Or this subtle change that was mentioned in today vndr: ~$2-5 billion Bria-IMT opportunity# changed to ~$2.5 billion Bria-IMT opportunity# Values are getting corrected.
1 replies
AliceFireSteam Sep 29, 7:54 PM
$BCTX Seems nobody noticed the DHT comment from Williams... That correlated with survival...
1 replies
letsdodiz Sep 29, 7:12 PM
$BCTX Highlights from today’s presentation 1. 144th event expected later this year. Data cleanup could take up to two months so the interim results could slip into 2027. 2. Next enrollment update will be enrollment completed, which is expected soon (within few months). 3. Cash not needed until Q2 2027 and the company is willing to stretch if needed to wait for interim results. Please add any new information you may have caught in the meeting.
2 replies
Biotechlineup Sep 29, 6:57 PM
$BCTX Just finished listening and added while the presentation was going on . My question was presented and answered. Very simple, they can’t lie about this. Very directly asked specific questions. They very clearly stated they are on track for year end interim results. They very clearly stated they have a cash run into 2027. Those two clarifications greatly de risked this stock. IMO worth adding .
0 replies
BHWinehouse Sep 29, 6:50 PM
$BCTX I added 15 minutes in
0 replies
BCTX20bMC Sep 29, 6:46 PM
$BCTX enough cash until mid 2027….bye bye shorts
0 replies